Compare RH & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RH | BEAM |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2011 | 2019 |
| Metric | RH | BEAM |
|---|---|---|
| Price | $129.57 | $30.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $167.00 | $50.75 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 06-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.31 | ★ 82.31 |
| EPS | ★ 6.31 | N/A |
| Revenue | ★ $1,193,046,000.00 | $24,000.00 |
| Revenue This Year | $8.39 | N/A |
| Revenue Next Year | $9.44 | $33.77 |
| P/E Ratio | $20.90 | ★ N/A |
| Revenue Growth | 24.52 | ★ 33.33 |
| 52 Week Low | $106.30 | $15.52 |
| 52 Week High | $256.78 | $36.44 |
| Indicator | RH | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 59.15 |
| Support Level | $127.00 | $22.24 |
| Resistance Level | $144.80 | $32.01 |
| Average True Range (ATR) | 5.82 | 1.81 |
| MACD | 0.78 | 0.01 |
| Stochastic Oscillator | 17.15 | 71.15 |
RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and is growing the presence of its hospitality business with 24 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.